Physician profile
John Goertz
NPI 1699709006
$8,170.36
in general payments reported to CMS, 2019-2025
26 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $441 · 2021: $618 · 2022: $3,629 · 2023: $1,066 · 2024: $1,137 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224 · Honoraria: $53.37 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.38 |
| Honoraria | $53.37 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,350.50 | 2020-2025 | Idosetr, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Alcon Vision LLC | $879.99 | 2019-2025 | Tryptyr, Hydrus Microstent, Clareon |
| Abbvie INC. | $601.21 | 2022-2025 | |
| Biotissue Holdings INC. | $558.26 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $333.34 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $307.98 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $290.78 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $284.02 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $213.55 | 2024-2025 | Xdemvy |
| Optos, INC. | $185.35 | 2022 | |
| Sun Pharmaceutical Industries INC. | $164.08 | 2021 | |
| Kala Pharmaceuticals, INC. | $138.41 | 2021 | |
| Samsara Vision | $135.77 | 2023 | |
| Sight Sciences, INC. | $129.10 | 2020 | |
| Rxsight INC | $118.87 | 2020-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.72 | 2020-2021 | |
| Dompe US, INC. | $72.71 | 2021-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $70.64 | 2023-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Horizon Therapeutics Plc | $65.94 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $55.44 | 2021-2023 | |
| Allergan, INC. | $28.78 | 2022 | |
| Omeros Corporation | $27.51 | 2020-2021 | |
| Ivantis, INC | $20.51 | 2021 | |
| Harrow Eye, LLC | $19.87 | 2025 | |
| Aerie Pharmaceuticals, INC. | $18.22 | 2021 | |
| The Cameron-Ehlen Group, INC. | $9.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.